Neuroendocrine regulation of food intake

Current Opinion in Gastroenterology

Volumn 24, Issue 2, 2008, Pages 223-229

  Chaptini, Louis ^a   Peikin, Steven ^a  

^a Division of Female Pelvic Medicine and Reconstructive Surgery   (United States)

Author keywords

Appetite; Energy homeostasis; Obesity

Indexed keywords

ADIPONECTIN; CHOLECYSTOKININ; EXENDIN 4; GHRELIN; GLUCAGON LIKE PEPTIDE; LEPTIN; OXYNTOMODULIN; PANCREAS POLYPEPTIDE; PEPTIDE YY;

DRUG EFFECT; ENERGY BALANCE; FOOD INTAKE; HOMEOSTASIS AND REGULATION; HUMAN; LOW DRUG DOSE; NEUROENDOCRINE SYSTEM; NONHUMAN; OBESITY; PREFRONTAL CORTEX; REVIEW; WEIGHT REDUCTION;

ADIPOSE TISSUE; ADULT; BARIATRIC SURGERY; CENTRAL NERVOUS SYSTEM; EATING; ENERGY METABOLISM; GASTROINTESTINAL HORMONES; HOMEOSTASIS; HORMONES; HUMANS; NEUROSECRETORY SYSTEMS; OBESITY;

EID: 40049102982     PISSN: 02671379     EISSN: None     Source Type: Journal    
DOI: 10.1097/MOG.0b013e3282f3f4d8     Document Type: Review

References (61)

1. Alonso-Alonso M, Pascual-Leone A. The right brain hypothesis for obesity. JAMA 2007; 297:1819-1822. An elegant commentary on the role of the right brain, especially the right prefrontal cortex, in the regulation of food intake. It highlights the interactions of reflective and reflexive eating pathways and the role of cognition in energy homeostasis.
2. Morton GJ, Cummings DE, Baskin DG, et al. Central nervous system control of food intake and body weight. Nature 2006; 443:289-295. A detailed review on the role of the CNS in energy homeostasis, with emphasis on the interaction between the brain and adiposity signals.
3. Abizaid A, Gao Q, Horvath TL. Thoughts for food: brain mechanisms and peripheral energy balance. Neuron 2006; 51:691-702.
4. Biebermann H, Castaneda TR, van Landeghem F, et al. A role for beta-melanocyte-stimulating hormone in human body-weight regulation. Cell Metab 2006; 3:141-146.
5. Lee YS, Challis BG, Thompson DA, et al. A POMC variant implicates beta-melanocyte-stimulating hormone in the control of human energy balance. Cell Metab 2006; 3:135-140.
6. Adan RA, Tiesjema B, Hillebrand JJ, et al. The MC4 receptor and control of appetite. Br J Pharmacol 2006; 149:815-827.
7. Arora S, Anubhuti. Role of neuropeptides in appetite regulation and obesity: a review. Neuropeptides 2006; 40:375-401. This comprehensive review discusses the role of neuropeptides secreted in the hypothalamus and in the periphery in the regulation of food intake.
8. Aronne LJ, Thornton-Jones ZD. New targets for obesity pharmacotherapy. Clin Pharmacol Ther 2007; 81:748-752. This paper highlights new advances in the pharmacological treatment of obesity and sheds some light on molecules under development and undergoing initial trials.
9. Erondu N, Gantz I, Musser B, et al. Neuropeptide Y5 receptor antagonism does not induce clinically meaningful weight loss in overweight and obese adults. Cell Metab 2006; 4:275-282. This paper looked at the effect of a potent, highly selective oral neuropeptide Y5 receptor antagonist on weight loss.
10. Regard M, Landis T. 'Gourmand syndrome': eating passion associated with right anterior lesions. Neurology 1997; 48:1185-1190.
11. Arias M, Crespo Iglesias JM, Perez J, et al. Kleine-Levin syndrome: contribution of brain SPECT in diagnosis. Rev Neurol 2002; 35:531-533.
12. Uher R, Treasure J. Brain lesions and eating disorders. J Neurol Neurosurg Psychiatry 2005; 76:852-857.
13. Tranel D, Bechara A, Denburg NL. Asymmetric functional roles of right and left ventromedial prefrontal cortices in social conduct, decision-making, and emotional processing. Cortex 2002; 38:589-612.
14. Delparigi A, Chen K, Salbe AD, et al. Successful dieters have increased neural activity in cortical areas involved in the control of behavior. Int J Obes (Lond) 2007; 31:440-448. An important paper that demonstrates the activation of cortical areas involved in controlling inappropriate behavioral responses in successful dieters.
15. Niswender KD, Schwartz MW. Insulin and leptin revisited: adiposity signals with overlapping physiological and intracellular signaling capabilities. Front Neuroendocrinol 2003; 24:1-10.
16. Badman MK, Flier JS. The adipocyte as an active participant in energy balance and metabolism. Gastroenterology 2007; 132:2103-2115. An important review of the role of the adipocyte in energy homeostasis.
17. Balthasar N, Coppari R, McMinn J, et al. Leptin receptor signaling in POMC neurons is required for normal body weight homeostasis. Neuron 2004; 42:983-991.
18. Bjorbaek C, Elmquist JK, Frantz JD, et al. Identification of SOCS-3 as a potential mediator of central leptin resistance. Mol Cell 1998; 1:619-625.
19. Howard JK, Cave BJ, Oksanen LJ, et al. Enhanced leptin sensitivity and attenuation of diet-induced obesity in mice with haploinsufficiency of Socs3. Nat Med 2004; 10:734-738.
20. Mori H, Hanada R, Hanada T, et al. Socs3 deficiency in the brain elevates leptin sensitivity and confers resistance to diet-induced obesity. Nat Med 2004; 10:739-743.
21. Qi Y, Takahashi N, Hileman SM, et al. Adiponectin acts in the brain to decrease body weight. Nat Med 2004; 10:524-529.
22. Fantuzzi G. Adipose tissue, adipokines, and inflammation. J Allergy Clin Immunol 2005; 115:911-919.
23. Wren AM, Bloom SR. Gut hormones and appetite control. Gastroenterology 2007; 132:2116-2130. An excellent review of the role of gut hormones in appetite regulation.
24. Cummings DE, Shannon MH. Roles for ghrelin in the regulation of appetite and body weight. Arch Surg 2003; 138:389-396.
25. Cowley MA, Smith RG, Diano S, et al. The distribution and mechanism of action of ghrelin in the CNS demonstrates a novel hypothalamic circuit regulating energy homeostasis. Neuron 2003; 37:649-661.
26. Riediger T, Traebert M, Schmid HA, et al. Site-specific effects of ghrelin on the neuronal activity in the hypothalamic arcuate nucleus. Neurosci Lett 2003; 341:151-155.
27. De Lartigue G, Dimaline R, Varro A, Dockray GJ. Cocaine- and amphetamine-regulated transcript: stimulation of expression in rat vagal afferent neurons by cholecystokinin and suppression by ghrelin. J Neurosci 2007; 27:2876-2882. This paper shows that cholecystokinin and ghrelin regulate CART expression in vagal afferent neurons in rats.
28. Le Roux CW, Neary NM, Halsey TJ, et al. Ghrelin does not stimulate food intake in patients with surgical procedures involving vagotomy. J Clin Endocrinol Metab 2005; 90:4521-4524.
29. Cummings DE, Purnell JQ, Frayo RS, et al. A preprandial rise in plasma ghrelin levels suggests a role in meal initiation in humans. Diabetes 2001; 50:1714-1719.
30. Tschop M, Wawarta R, Riepl RL, et al. Postprandial decrease of circulating human ghrelin levels. J Endocrinol Invest 2001; 24:RC19-RC21.
31. Drazen DL, Vahl TP, D'Alessio DA, et al. Effects of a fixed meal pattern on ghrelin secretion: evidence for a learned response independent of nutrient status. Endocrinology 2006; 147:23-30. This paper shows that anticipation of eating, as well as fasting/feeding status, influences pre and postprandial plasma ghrelin levels in rats.
32. Sugino T, Yamaura J, Yamagishi M, et al. A transient surge of ghrelin secretion before feeding is modified by different feeding regimens in sheep. Biochem Biophys Res Commun 2002; 298:785-788.
33. Miura H, Tsuchiya N, Sasaki I, et al. Changes in plasma ghrelin and growth hormone concentrations in mature Holstein cows and three month-old calves. J Anim Sci 2004; 82:1329-1333.
34. Soriano-Guillen L, Barrios V, Campos-Barros A, Argente J. Ghrelin levels in obesity and anorexia nervosa: effect of weight reduction or recuperation. J Pediatr 2004; 144:36-42.
35. Williams DL, Grill HJ, Cummings DE, Kaplan JM. Overfeeding-induced weight gain suppresses plasma ghrelin levels in rats. J Endocrinol Invest 2006; 29:863-868.
36. Theander-Carrillo C, al Wiedmer P, Cettour-Rose P, et al. Ghrelin action in the brain controls adipocyte metabolism. J Clin Invest 2006; 116:1983-1993. This paper examines the central action of ghrelin and its role in the regulation of adipocyte metabolism.
37. Murphy KG, Bloom SR. Gut hormones and the regulation of energy homeostasis. Nature 2006; 444:854-859. A complete review of the role of gut hormones in the regulation of energy homeostasis.
38. Beglinger C, Degen L, Matzinger D, et al. Loxiglumide, a CCK-A receptor antagonist, stimulates calorie intake and hunger feelings in humans. Am J Physiol Regul Integr Comp Physiol 2001; 280:R1149-R1154.
39. Matson CA, Reid DF, Cannon TA, Ritter RC. Cholecystokinin and leptin act synergistically to reduce body weight. Am J Physiol Regul Integr Comp Physiol 2000; 278:R882-R890.
40. Clerc P, Coll Constans MG, Lulka H, et al. Involvement of cholecystokinin 2 receptor in food intake regulation: hyperphagia and increased fat deposition in cholecystokinin 2 receptor-deficient mice. Endocrinology 2007; 148:1039-1049. This study demonstrates that the CCK-2 receptor plays a role in the control of food intake.
41. Batterham RL, Cowley MA, Small CJ, et al. Gut hormone PYY(3-36) physiologically inhibits food intake. Nature 2002; 418:650-654.
42. Batterham RL, Cohen MA, Ellis SM, et al. Inhibition of food intake in obese subjects by peptide YY3-36. N Engl J Med 2003; 349:941-948.
43. Chelikani PK, Haver AC, Reidelberger RD. Intravenous infusion of peptide YY(3-36) potently inhibits food intake in rats. Endocrinology 2005; 146:879-888.
44. Adams SH, Won WB, Schonhoff SE, et al. Effects of peptide YY[3-36] on short-term food intake in mice are not affected by prevailing plasma ghrelin levels. Endocrinology 2004; 145:4967-4975.
45. Degen L, Oesch S, Casanova M, et al. Effect of peptide YY3-36 on food intake in humans. Gastroenterology 2005; 129:1430-1436.
46. Le Roux CW, Batterham RL, Aylwin SJ, et al. Attenuated peptide YY release in obese subjects is associated with reduced satiety. Endocrinology 2006; 147:3-8. This study shows that obese subjects have a PYY deficiency that reduces satiety and reinforces obesity.
47. Batterham RL, Le Roux CW, Cohen MA, et al. Pancreatic polypeptide reduces appetite and food intake in humans. J Clin Endocrinol Metab 2003; 88:3989-3992.
48. Jesudason DR, Monteiro MP, McGowan BM, et al. Low-dose pancreatic polypeptide inhibits food intake in man. Br J Nutr 2007; 97:426-429.
49. Ueno N, Inui A, Iwamoto M, et al. Decreased food intake and body weight in pancreatic polypeptide-overexpressing mice. Gastroenterology 1999; 117:1427-1432.
50. Kojima S, Ueno N, Asakawa A, et al. A role for pancreatic polypeptide in feeding and body weight regulation. Peptides 2007; 28:459-463. A review that highlights the mechanisms and pathways by which pancreatic polypeptide plays a role in feeding and weight regulation.
51. Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology 2007; 132:2131-2157. A detailed review of the biological role of incretins.
52. Edwards CM, Stanley SA, Davis R, et al. Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers. Am J Physiol Endocrinol Metab 2001; 281:E155-E161.
53. Todd JF, Edwards CM, Ghatei MA, et al. Subcutaneous glucagon-like peptide-1 improves postprandial glycaemic control over a 3-week period in patients with early type 2 diabetes. Clin Sci (Lond) 1998; 95:325-329.
54. Todd JF, Wilding JP, Edwards CM, et al. Glucagon-like peptide-1 (GLP-1): a trial of treatment in noninsulin-dependent diabetes mellitus. Eur J Clin Invest 1997; 27:533-536.
55. Gutzwiller JP, Goke B, Drewe J, et al. Glucagonlike peptide-1: a potent regulator of food intake in humans. Gut 1999; 44:81-88.
56. Buse JB, Henry RR, Han J, et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 2004; 27:2628-2635.
57. DeFronzo RA, Ratner RE, Han J, Kim DD, et al. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005; 28:1092-1100.
58. Wynne K, Park AJ, Small CJ, et al. Oxyntomodulin increases energy expenditure in addition to decreasing energy intake in overweight and obese humans: a randomised controlled trial. Int J Obes 2006; 30:1729-1736.
59. Borg CM, le Roux CW, Ghatei MA, et al. Progressive rise in gut hormone levels after Roux-en-Y gastric bypass suggests gut adaptation and explains altered satiety. Br J Surg 2006; 93:210-215.
60. Le Roux CW, Aylwin SJ, Batterham RL, et al. Gut hormone profiles following bariatric surgery favor an anorectic state, facilitate weight loss, and improve metabolic parameters. Ann Surg 2006; 243:108-114. This paper shows that patients with Roux-en-Y gastric bypass had increased postprandial plasma PYY and GLP-1, favoring enhanced satiety.
61. Neary NM, Small CJ, Druce MR, et al. Peptide YY3-36 and glucagon-like peptide-17-36 inhibit food intake additively. Endocrinology 2005; 146:5120-5127.